



Published in final edited form as:

J Alzheimers Dis. 2019 ; 69(3): 817–827. doi:10.3233/JAD-190154.

Higher Body Mass Index Is Associated with Lower Cortical Amyloid- β Burden in Cognitively Normal Individuals in Late-Life

Vineeth Thirunavu^a, Austin McCullough^b, Yi Su^c, Shaney Flores^b, Aylin Dincer^b, John C. Morris^{d,e}, Carlos Cruchaga^{d,f}, Tammie L.S. Benzinger^{b,d}, Brian A. Gordon^{b,d,*}

^aDepartment of Biology, Washington University in St. Louis, MO, USA

^bDepartment of Radiology, Washington University in St. Louis, MO, USA

^cBanner Alzheimer's Institute, Phoenix, AZ, USA

^dKnight Alzheimer Disease Research Center, Washington University in St. Louis, MO, USA

^eDepartment of Neurology, Washington University in St. Louis, MO, USA

^fDepartment of Psychiatry, Washington University in St. Louis, MO, USA

Abstract

Background—Both low and high body mass index (BMI) have been associated with an increased risk of dementia, including that caused by Alzheimer's disease (AD). Specifically, high middle-age BMI or a low late-age BMI has been considered a predictor for the development of AD dementia. Less studied is the relationship between BMI and AD pathology.

Objective—We explored the association between BMI and cortical amyloid- β ($A\beta$) burden in cognitively normal participants that were either in mid-life (45–60 years) or late-life (>60).

Methods—We analyzed cross-sectional baseline data from the Knight Alzheimer Disease Research Center (ADRC) at Washington University. $A\beta$ pathology was measured in 373 individuals with $A\beta$ PET imaging and was quantified using Centiloid units. We split the cohort into mid- and late-life groups for analyses ($n = 96$ and $n = 277$, respectively). We ran general linear regression models to predict $A\beta$ levels from BMI while controlling for age, sex, years of education, and *APOE4* status. Analyses were also conducted to test the interaction between BMI and *APOE4* genotype and between BMI and sex.

Results—Higher BMI was associated with lower cortical $A\beta$ burden in late-life ($\beta = -0.81$, $p = 0.0066$), but no relationship was found in mid-life ($\beta = 0.04$, $p > 0.5$). The BMI \times *APOE4+* and BMI \times male interaction terms were not significant in the mid-life ($\beta = 0.28$, $p = 0.41$; $\beta = 0.64$, $p = 0.13$) or the late-life ($\beta = 0.17$, $p > 0.5$; $\beta = 0.50$, $p = 0.43$) groups.

Conclusion—Higher late-life BMI is associated with lower cortical $A\beta$ burden in cognitively normal individuals.

*Correspondence to: Brian A. Gordon, Washington University School of Medicine, 660 South Euclid, Campus Box 8225, St. Louis, MO 63110, USA. Tel.: +1 314 747 7354; bagordon@wustl.edu.

Authors' disclosures available online (<https://www.j-alz.com/manuscript-disclosures/19-0154r1>).

Keywords

Alzheimer disease; amyloid- β ; apolipoproteins E; body mass index; obesity; positron emission tomography

INTRODUCTION

Alzheimer's disease (AD) is a debilitating, progressive neurodegenerative disease that is the leading cause of dementia in the United States [1, 2]. The disease disproportionately affects the population aged 65 and older. Roughly 96% of total AD cases in the U.S. fall within this age group [3]. As the number of 65+ individuals in the U.S. is projected to increase from 53 million to 88 million by 2050, the number of Americans with AD will rapidly escalate [4]. Given that \$277 billion was spent on AD in 2017 [5], it is imperative that risk factors are identified in cognitively normal populations to better understand how disease progression might be controlled and to minimize future AD-related healthcare expenditures. Obesity, like AD, also poses a significant public health problem in the U.S. One in five Americans are morbidly obese, and obesity itself has been linked with an increased risk of diabetes, coronary heart disease, and cancer [6]. Although higher body mass index (BMI) is generally associated with adverse health outcomes [7, 8], there is evidence that large body size is actually beneficial for those with certain chronic cardiovascular, pulmonary, and renal diseases [9]. These counterintuitive findings also appear in studies examining the relationship between obesity and dementia [10–15].

Generally, epidemiological studies show that being overweight increases the risk [10, 11] of developing a dementing disorder (vascular, AD, etc.). However, there has also been research showing no increased risk of dementia [12–14] or even a reduced risk of dementia [15]. When examining AD specifically, epidemiological work has shown being overweight is both associated with an increased risk [16, 17] and a decreased risk [9, 18–20]. These inconsistent findings relating obesity to an increased risk of dementia may arise from the heterogeneous nature of the populations being studied. Specifically, the obesity-dementia relationship seems to differ for those in mid-life versus late-life [10, 21–26], and this difference may be attributed to weight loss occurring near the onset of dementia [25, 26] or a long preclinical phase that is associated with weight loss, sarcopenia, and fat mass reduction [27–32]. Due to these findings, it is imperative to study the obesity-dementia relationship separately for each age group within a cognitively normal cohort.

Prior work has primarily focused on how obesity impacts the risk of developing dementia. As a result, it is unclear if changes in obesity directly impact AD pathology, or instead just represent co-morbid processes that impact cognition directly. Animal work suggests that obesity and diabetes can directly influence the accumulation of AD pathology [33–38]. In humans, only a modest number of studies have directly examined the relationship between obesity measured with BMI and AD pathology [25, 39–44] using biomarkers such as cerebrospinal fluid (CSF) amyloid- β ($A\beta$) 1–42 [43], CSF total tau [40], and cortical $A\beta$ as measured by positron emission tomography [39, 44]. These studies have found an association between a greater weight and lower AD pathology. While this prior work has

been informative, these studies typically have small sample sizes or do not take into the account both how the relationship of BMI on AD pathology may vary as a function of both age group and *APOE4* genotype, the latter of which has been shown to modify the AD-body composition relationship [39, 40].

We sought to further characterize the relationships between obesity and AD by examining the cross-sectional relationship between BMI and cortical A β burden as measured by PET in cognitively normal (CN) participants. We examined the relationship between weight and AD pathology in both those in mid-life (45–60 years) and late life (>60) in a cross-sectional cohort. Based upon prior work, we hypothesized that in CN mid-life individuals, higher BMI will be associated with elevated cortical A β burden. In CN late-life individuals, we hypothesized that higher BMI will be associated with lower cortical A β burden. Additionally, we were interested in whether the BMI-A β relationship is modified by the presence of an *APOE e4* allele or by sex.

METHODS

Participants

Participants were selected from ongoing longitudinal studies of aging and dementia from the Knight Alzheimer Disease Research Center (ADRC) at Washington University in St. Louis. Cognitive status in these participants was assessed using the clinical dementia rating (CDR) [45]. Participants were required to be clinically normal (CDR = 0), have an A β PET scan, have information on demographic variables (age, sex, and education), have information on *APOE* genotype, and have a recorded height and weight (to calculate BMI) from the day of their scan. Participants were classified as being mid-life (45–60 years) and late-life (>60 years).

Imaging acquisition and processing

Magnetic resonance imaging (MRI) scans were obtained using 3 Tesla volumetric T1-weighted MRI scanners following the ADNI protocol (<http://adni.loni.usc.edu/methods/documents/mri-protocols/>) and processed through FreeSurfer, version 5.3 [46] (Martinos Center, Boston, MA), as previously described [47]. The T1-weighted images were used for measurements of hippocampal volumes adjusted for total intracranial volumes using a regression approach, and for measurements of cortical volumes and ventricular volumes.

A β PET imaging was completed using two tracers: [¹⁸F] florbetapir (AV-45, $n = 18$) and [¹¹C]- Pittsburgh Compound B (PiB, $n = 355$). Data were analyzed with an in-house pipeline using regions of interest (ROIs) derived from FreeSurfer 5.3 segmentations [47]. Standardized Uptake Value ratios (SUVRs) were calculated for the time windows between 50–70 min post-injection for AV45 and 30–60 min post-injection for PiB using cerebellar cortex as a reference region. Partial volume effects were corrected for using a regional spread function (RSF) technique [48, 49].

To assess global A β burden, the arithmetic mean of SUVRs from the FreeSurfer ROIs in the prefrontal cortex, precuneus, gyrus rectus, and lateral temporal regions were calculated as the mean cortical SUVR (MCSUVR), as previously published [47]. To combine the data

from both tracers, partial volume corrected SUVRs were converted into Centiloid units [50, 51]. A β value of 0 on the scale represents the mean A β burden of a young control group with no A β pathology. A value of 100 represents the mean A β burden of an AD group [51].

The equations to convert AV45 and PiB MCSU-VRRSF to Centiloid Units derived at our center are:

$$53.6 * AV45 \text{ MCSU-VRRSF} - 43.2 = \text{Centiloid Units}$$

$$45 * PiB \text{ MCSU-VRRSF} - 47.5 = \text{Centiloid Units}$$

Body mass index

Each participant had a height and weight measurement taken the day of their PET scan. The standard formula for calculating BMI as defined by the NIH was used to transform height and weight into participant BMI [52]. As it is common to examine categorical groupings for additional analyses, we investigated the BMI-A β relationship using BMI subdivisions rather than a continuous value of BMI. The subdivisions were defined using current NIH guidelines: underweight (BMI <18.5), normal (BMI 18.5–24.9), overweight (BMI 25–29.9), and obese (BMI >30). The underweight subdivision was not used for additional analyses as there were too few individuals in this group ($n = 5$).

APOE genotype

DNA was extracted from peripheral blood samples using standard procedures, as previously described [53]. *APOE4* carrier status was determined by having at least one *APOE4* allele.

Statistical analyses

Statistical analyses were performed in R, version 3.5.1. Separate general linear regression models (GLMs) incorporated continuous measures of BMI and cortical A β burden (measured in Centiloid units). Primary models included the main effect of BMI, age group (mid-life/late-life), an interaction term of BMI and age group as well as covariates for *APOE4* carrier status, sex, age, and education. Additional linear regressions were run separately for each age group while including a main effect of BMI and all covariates. Partial regression plots were used to take into account the effect of multiple independent variables.

Although BMI is continuous, it is often conceptualized as an ordinal measure. For additional analyses, we investigated the differences in mean cortical A β burden between BMI groups (normal, overweight, obese) by computing a one-way analysis of variance (ANOVA) testing whether there was a main effect of BMI group on A β level followed by a multiple pairwise-comparison *t*-test between the means of the BMI groups.

As prior work suggests an interaction between BMI and *APOE* genotype, we also investigated the association of continuous measures of BMI and cortical A β burden by including an interaction term for continuous BMI and *APOE4* status within each age group.

Finally, we also investigated the interaction between BMI and sex by including an interaction term for continuous BMI and sex within each age group.

RESULTS

Baseline characteristics

Based upon the selection criteria, all participants were CN (global CDR = 0). Those in mid-life ($n = 96$) were on average 53.5 years of age (range: 45–60), college educated (mean: 16.3 years of education), 72.9% female, 35.4% had at least one *APOE4* allele (E4+). Those in mid-life had a mean Mini-Mental State Examination score of 28.9 and a mean CDR sum of boxes (CDR-SOB) of 0.0053. Those in late-life ($n = 277$) were on average 71.4 years of age (range: 61–100), college educated (mean: 15.8 years of education), 59.9% female, and 28.5% E4+. Those in late-life had a mean MMSE score of 28.8 and a mean CDR-SOB of 0.033 (see Table 1 for demographics).

In both the mid- and late-life groups, the majority of participants were overweight or obese (64.6% and 59.6%, respectively). Due to the small number of underweight participants in both groups, underweight participants were excluded in analyses investigating BMI subdivisions given the lack of power. *APOE4* carrier status, education, age, and other baseline characteristics were not significantly different between BMI subdivisions in either the mid- or late-life groups as assessed by *t*-tests.

Continuous BMI and cortical A β burden in mid- and late-life

The relationship between a continuous measure of BMI and cortical A β burden is presented in Fig. 1. When modeling an interaction between BMI and age group for the whole cohort, the BMI \times age-group interaction term was significant ($p = 0.0309$). Thus, there is a differential effect of BMI in mid-life versus late-life. In the late-life cohort, higher BMI was associated with a lower cortical A β burden ($\beta = -0.82$, $p = 0.0074$) in the linear regression model after including age, sex, years of education, and *APOE4* carrier status. BMI in the mid-life cohort did not show any significant association with cortical A β burden ($\beta = 0.03$, $p > 0.5$) after adjusting for the same variables (Fig. 2). These results remained the same after excluding the four individuals with highest BMI.

The main effect of *APOE4* carrier status was significant in both the mid- and late-life models, ($\beta = 6.1$, $p = 0.0012$ and $\beta = 18.1$, $p < 0.001$, respectively), with *APOE4* carriers having elevated cortical A β burden compared to non-carriers. Age was also significant in both the mid- and late-life models ($\beta = 0.51$, $p = 0.0283$ and $\beta = 0.90$, $p < 0.001$, respectively), with higher age being associated with elevated cortical A β burden.

Differences in cortical A β burden by BMI group in mid- and late-life

To test group differences in mean cortical A β burden between the three BMI groups (normal, overweight, and obese) in mid- or late-life, we computed a one-way ANOVA test examining the main effect of BMI group separately for the late-life and mid-life cohorts. The ANOVAs showed that there was a significant difference in the mean cortical A β burden between BMI groups in late-life ($F_{2,269} = 5.60$, $p = 0.0042$). Pairwise-comparison *t*-tests show a significant difference in mean cortical A β burden between the normal and obese groups in late-life ($p < 0.001$) (Fig. 3A). The mean cortical A β burden of the overweight

group was not significantly different from that of the normal group ($p = 0.0763$) or the obese group ($p = 0.0616$) in late-life (Fig. 3A).

There was no significant main effect of BMI group on A β burden in mid-life ($F_{2,93} = 0.069$, $p > 0.5$). Even in the pair-wise contrasts, there were no significant differences between any BMI groups in mid-life (Fig. 3B), with $p > 0.5$ for all three comparisons.

We then utilized a general linear regression model for late-life participants with categorical BMI and controlled for age, sex, years of education, and *APOE4* status. Compared to a normal BMI, being classified as overweight or obese was significantly associated with a lower cortical A β burden ($\beta = -7.7$, $p = 0.0499$ and $\beta = -12.4$, $p = 0.0033$, respectively). E4+ and age both remained significant in the model with categorical BMI for late-life ($\beta = 17.8$, $p < 0.001$ & $\beta = 0.87$, $p < 0.001$, respectively).

Although by definition sorting individuals into BMI groups limits the ranges values can take, prior work [39] examined whether there was a significant effect of continuous BMI levels *within* the different BMI categories. Therefore, we also tested the association between continuous BMI and cortical A β burden within the three BMI categories in late-life individuals while controlling for age, sex, years of education, and *APOE4* status. We found no significant association between continuous BMI and cortical A β burden in any of these groups (normal: $\beta = -0.42$, $p > 0.5$; overweight: $\beta = -0.19$, $p > 0.5$; obese: $\beta = -0.03$, $p > 0.5$).

Differences in cortical A β burden by *APOE4* group in mid- and late-life

Additional models for the mid-life and late-life participants added a continuous BMI \times *APOE4+* interaction term to the primary model (from Fig. 1) in order to evaluate if there is a differential effect of BMI in *APOE4* carriers versus non-carriers. This interaction term was not significant in the mid-life ($\beta = 0.33$, $p = 0.296$) or the late-life ($\beta = 0.29$, $p > 0.5$) groups (Fig. 4). As expected, age remained significant in both the mid-life ($\beta = 0.50$, $p = 0.035$) and late-life ($\beta = 0.89$, $p < 0.001$) models with the interaction term.

Differences in cortical A β burden by sex in mid- and late-life

Additional models for the mid-life and late-life participants added a continuous BMI \times male interaction term to the primary model (from Fig. 1) in order to evaluate if there is a differential effect of BMI in males versus females. This interaction term was not significant in the mid-life ($\beta = 0.64$, $p = 0.13$) or the late-life ($\beta = 0.50$, $p = 0.43$) groups.

A summary of the additional analyses can be seen in Table 2.

Total hippocampal volume

We also ran a general linear regression model assessing the relationship between continuous BMI and total hippocampal volume. The models were adjusted for the same covariates as in the A β analysis. We found no relationship between continuous BMI and total hippocampal volume in either the mid-life ($\beta = -11.99$, $p = 0.46$). or late-life ($\beta = 4.0$, $p > 0.5$) groups.

DISCUSSION

A high percentage of adults in Western countries are overweight or obese, just as 61% of the total cohort in this study was overweight or obese. Trends indicate that the percentages of adults in these categories will only increase in coming years [54]. The rising prevalence of obesity has the potential to have important implications for the cognitive health of adults in different stages of life. Prior work suggested there might be a relationship between obesity and the risk for developing dementia. In our analyses, we examined whether a cross-sectional relationship existed between cortical A β burden, a biomarker reflective of AD pathophysiology, and BMI in both mid- and late-life cognitively normal individuals. We found that higher BMI was associated with lower cortical A β burden in late-life participants. Although prior epidemiological work suggests obesity increases the risk of AD [10, 11, 16], the current finding showing a *negative* relationship between BMI and A β burden is consistent with similar relationships found using similar cohorts [39, 40].

When examining BMI as a continuous variable we found that greater levels of BMI were associated with lower levels of A β burden. This pattern was present in the late-life, but not the mid-life cohort. Although some previous studies included individuals with mild cognitive impairment and mild AD dementia, we found that this relationship persists even in a large cohort that was limited to participants who were cognitively normal at baseline. This finding shows that BMI and cortical amyloid burden can be directly related, and it gives a platform for future work to elucidate whether the BMI-amyloid relationship is reflected by comorbid process or some causal mechanism. If an aspect of body composition can become a biomarker for AD, then identification of AD may be easier and expenditures may be minimized.

When examining BMI as a categorical variable (normal, overweight, and obese), we found that there was a significant difference in the mean cortical A β burden between BMI groups in late-life but not in mid-life. As seen with our analyses of BMI as a continuous variable, the relationship was such that the categories representing greater levels of obesity on average had less A β burden measured with PET. Prior work using a cognitively normal cohort or a mixed cognitively normal and impaired cohort has found effects of continuous levels of BMI within categories [39, 40]. We found that when dividing the late-life group into three distinct BMI categories (normal, overweight, and obese), the association between BMI and cortical A β burden was non-significant in each of these three groups. Thus, our results show that the differences in BMI within a restricted BMI range have less predictive power of cortical A β burden than the BMI range an individual falls within. This is unsurprising as classifying individuals into BMI groups constrains the range of BMI values, limiting the sensitivity as well as the interpretability of such analyses.

The results of this study support some of the findings from previous literature. Specifically, higher BMI in late-life is associated with lower pathology [40–44]. However, our study does not find evidence that higher BMI is associated with an increased risk of AD in mid-life participants. As evidenced by our BMI x age-group model, the effect of BMI on cortical amyloid burden differs by age group. One possible explanation for the non-significant finding in the mid-life group, as opposed to the significant finding in the late-life group, is

that the range of Centiloid values is much narrower for the mid-life group. With greater longitudinal data it may also be possible that mid-life obesity would later predict biomarkers in late-life.

We were also interested in whether the BMI-A β relationship is modified by the presence of an *APOE* ϵ 4 allele or by sex. *APOE*4 largely enhances A β pathology [55, 56] and is associated with greater rates of cognitive decline [57–60], so it is possible that being E4+ obscures any relationship between BMI and A β . Alternatively, secondary health factors may only exacerbate AD pathology in those with a predisposition toward elevated A β burden. There is also a suggestion that A β accumulation in E4+ individuals is moderated by leptin signaling in the hypothalamus and may in itself promote weight loss [61], such that the inverse relationship between BMI and A β may be stronger in E4+ individuals. However, we found no significant BMI by *APOE*4 interactions in either mid-life or late-life, unlike a few previous studies [39, 61]. Additionally, we were interested in sex as a modifier of the BMI-A β relationship, as many studies have found sex differences in AD [62–64]. We did not find any significant BMI by sex interactions in either mid-life or late-life. Previous studies have shown differences in brain atrophy rates [62], cognitive decline [62, 63, 65], mortality [66], and CSF A β ₁₋₄₂ [64] but not A β measured with PET [62], so our finding is unsurprising.

The inverse relationship of BMI-A β in late-life is counterintuitive to studies that have shown BMI is associated with adverse health outcomes [7, 8]. However, this “obesity paradox” also appears in AD and dementia. In 40–45 year olds, obesity has been shown to increase the risk of dementia later in life [21]. However, lower BMI in those aged over 65 is related to an increased risk of dementia, AD, and vascular dementia [10]. Higher late-life BMI is also indicative of good health status [18], reduced risk of dementia [19], and better cognitive performance [20]. The results of our study support one component of the “obesity paradox” in AD. Specifically, that higher BMI in late-life is associated with lower pathology, as other studies have shown [40–44]. However, our study does not support the other component of the “obesity paradox” because we did not find that higher BMI is associated with an increased risk of AD in mid-life participants. This relationship should be explored in a larger sample of mid-life participants with longitudinal AD pathology data to show the effects of an increasing BMI or sustained high BMI over time. This may shed light on the relationship between a higher BMI and an increased risk of AD in mid-life as reported by various studies [21, 67, 68] and the possibility that the predictive ability of BMI changes over time.

This study has several limitations. Firstly, BMI is a nonspecific measure of body composition and may not accurately reflect the amount and distribution of body fat [27, 69, 70]. Because the location of adipose tissue has been shown to be important in predicting dementia risk [70], a more specific measure of adiposity (e.g., waist circumference, percent body fat, and skinfold thickness) may have better predictive ability of AD risk. In addition, there is a greater misclassification inherent in BMI at mid-life in comparison to late-life [11]. The variation of adiposity in an individual throughout life stages warrants a more accurate measurement of adiposity that can be used in future studies relating BMI and AD pathology.

Our study did not assess the relationship between BMI and A β over time. As obesity represents a chronic condition, it may be necessary to examine the relationship between obesity and AD pathology over the course of decades. Such analyses would also be able to take into account common weight declines that occur before clinical AD onset [71]. Additionally, a longitudinal analysis could shed light on the association between BMI and rate of A β accumulation. We would also be able to assess if mid-life obesity predicts AD or dementia in late-life, as indicated by other studies [21, 67, 68]. The limitations of our data indicate that our results should not be interpreted as evidence for a temporal or causal relationship between BMI and A β .

It is also possible that BMI is related to other biomarkers (e.g., CSF A β , total tau, p-tau, tau PET, [¹⁸F]-fluorodeoxyglucose PET, and structural MR). It would be worthwhile to see if lower late-life BMI is associated not only with an elevated A β burden but also a greater rate of tau accumulation or neurodegeneration after AD onset. Future studies should investigate the relationship between BMI and these other biomarkers in an effort to isolate the associations between BMI, AD risk, and pathology after AD onset. Finally, any group of individuals who agree to participate in longitudinal studies in which molecular biomarkers of AD are obtained are not representative of the population from which they are recruited, so our results may not be generalizable.

Our study also had a number of strengths. Our sample of CN adults at baseline was large, especially for the late-life group. The primary models accounted for multiple demographic variables and the primary genetic risk factor for sporadic AD—*APOE* genotype. Additionally, we were able to investigate the relationship of continuous BMI and cortical A β in BMI and *APOE4* subdivisions. Furthermore, we were to directly relate a high A β burden, a marker of increased dementia risk, directly with BMI in cognitively normal elderly. Future studies will be able to use this baseline data and harmonize with other databases that have been successfully enrolling cognitively normal participants at baseline and tracking multiple AD biomarkers in these same participants over time.

Ultimately, exploring the relationship between BMI and AD biomarkers is important to better quantify risk of progressing to symptomatic stages of AD. The results from our study reinforce the need to monitor unintentional weight loss closely in older adults. Future studies should investigate the longitudinal association between adiposity and A β and examine whether the association between BMI and AD is mediated by possible confounding factors, like cardiovascular health, diabetes, and other disease conditions.

ACKNOWLEDGMENTS

YS is supported in part by BrightFocus Foundation grant A2017272S, A2017330S; Alzheimer's Association Research Grant AARG-17-532945; Arizona Alzheimer's Research Consortium; and NIH/NIA R01AG055444, R01AG031581. Funding for the analyses was provided by the Longer Life Foundation.

Additional sources of support: NIH: P50AG005681, P01AG026276, P01AG003991, UL1TR000448, (1P30NS098577) and R01 EB009352. Non-NIH: The Charles and Joanne Knight Alzheimer Disease Research Center Support Fund, The David and Betty Farrell Medical Research Fund, The Daniel J Brennan Alzheimer Research Fund, The Thomas E. Brew Foundation Fund, The Fred Simmons and Olga Mohan Alzheimer Research Support Fund, The Barnes-Jewish Hospital Foundation (BJHF), The Willman Scholar Fund (BJHF), Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly).

REFERENCES

- [1]. Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizek LP, Bennett DA (2012) The natural history of cognitive decline in Alzheimer's disease. *Psychol Aging* 27, 1008–1017. [PubMed: 22946521]
- [2]. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, Waters C, Jimison P, Shepherd E, Sevush S, Graff-Radford N, Newland D, Todd M, Miller B, Gold M, Heilman K, Doty L, Goodman I, Robinson B, Pearl G, Dickson D, Duara R (2002) Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. *Alzheimer Dis Assoc Disord* 16, 203–212. [PubMed: 12468894]
- [3]. Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. *Neurology* 80, 1778–1783. [PubMed: 23390181]
- [4]. U.S. Government Publishing Office, U.S. Census Bureau, International Population Reports, P95/16–1, An Aging World: 2015, Last updated 2016, Accessed on 2016.
- [5]. (2017) 2017 Alzheimer's disease facts and figures. *Alzheimers Dement* 13, 325–373.
- [6]. Agha M, Agha R (2017) The rising prevalence of obesity. *Int J Surg Oncol* 2, e17.
- [7]. Zamboni M, Mazzali G, Zoico E, Harris TB, Meigs JB, Di Francesco V, Fantin F, Bissoli L, Bosello O (2005) Health consequences of obesity in the elderly: A review of four unresolved questions. *Int J Obes* 29, 1011–1029.
- [8]. Stewart R, Masaki K, Xue Q-L, Peila R, Petrovitch H, White LR, Launer LJ (2005) A 32-year prospective study of change in body weight and incident dementia: The Honolulu-Asia Aging Study. *Arch Neurol* 62, 55–60. [PubMed: 15642850]
- [9]. Lainscak M, von Haehling S, Doehner W, Anker SD (2012) The obesity paradox in chronic disease: Facts and numbers. *J Cachexia Sarcopenia Muscle* 3, 1–4. [PubMed: 22450395]
- [10]. Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L (2011) Midlife overweight and obesity increase late-life dementia risk: A population-based twin study. *Neurology* 76, 1568–1574. [PubMed: 21536637]
- [11]. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT, Luchsinger JA (2009) Midlife and late-life obesity and the risk of dementia. *Arch Neurol* 66, 336–342. [PubMed: 19273752]
- [12]. Singh-Manoux A, Dugravot A, Shipley M, Brunner EJ, Elbaz A, Sabia S, Kivimaki M (2018) Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. *Alzheimers Dement* 14, 178–186. [PubMed: 28943197]
- [13]. Østergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, Perry JRB, Boehme KL, Walter S, Kauwe JS, Gibbons LE, Larson EB, Powell JF, Langenberg C, Crane PK, Wareham NJ, Scott RA, Crane PK, Wareham NJ, Scott RA (2015) Associations between potentially modifiable risk factors and Alzheimer disease: A Mendelian randomization study. *PLoS Med* 12, e1001841. [PubMed: 26079503]
- [14]. Mukherjee S, Walter S, Kauwe JSK, Saykin AJ, Bennett DA, Larson EB, Crane PK, Glymour MM, Adult Changes in Thought Study Investigators, Religious Orders Study/Memory and Aging Project Investigators, Alzheimer's Disease Genetics Consortium (2015) Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses. *Alzheimers Dement* 11, 1439–1451. [PubMed: 26079416]
- [15]. Qizilbash N, Gregson J, Johnson ME, Pearce N, Douglas I, Wing K, Evans SJW, Pocock SJ (2015) BMI and risk of dementia in two million people over two decades: A retrospective cohort study. *Lancet Diabetes Endocrinol* 3, 431–436. [PubMed: 25866264]
- [16]. Luchsinger JA, Gustafson DR (2009) Adiposity and Alzheimer's disease. *Curr Opin Clin Nutr Metab Care* 12, 15–21. [PubMed: 19057182]
- [17]. Luchsinger JA, Mayeux R (2007) Adiposity and Alzheimer's disease. *Curr Alzheimer Res* 4, 127–134. [PubMed: 17430235]
- [18]. Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D, Fratiglioni L (2008) Late-life body mass index and dementia incidence: Nine-year follow-up data from the Kungsholmen Project. *J Am Geriatr Soc* 56, 111–116. [PubMed: 18028342]

- [19]. Hughes TF, Borenstein AR, Schofield E, Wu Y, Larson EB (2009) Association between late-life body mass index and dementia: The Kame Project. *Neurology* 72, 1741–1746. [PubMed: 19451529]
- [20]. Kuo H- K, Jones RN, Milberg WP, Tennstedt S, Talbot L, Morris JN, Lipsitz LA (2006) Cognitive function in normal-weight, overweight, and obese older adults: An analysis of the advanced cognitive training for independent and vital elderly cohort. *J Am Geriatr Soc* 54, 97–103. [PubMed: 16420204]
- [21]. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K (2005) Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. *BMJ* 330, 1360. [PubMed: 15863436]
- [22]. Gorospe EC, Dave JK (2006) The risk of dementia with increased body mass index. *Age Ageing* 36, 23–29. [PubMed: 17124253]
- [23]. Chuang Y- F, An Y, Bilgel M, Wong DF, Troncoso JC, O'Brien RJ, Breitner JC, Ferruci L, Resnick SM, Thambisetty M (2016) Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation. *Mol Psychiatry* 21, 910–915. [PubMed: 26324099]
- [24]. Rosengren A, Skoog I, Gustafson D, Wilhelmsen L (2005) Body mass index, other cardiovascular risk factors, and hospitalization for dementia. *Arch Intern Med* 165, 321–326. [PubMed: 15710796]
- [25]. White H, Pieper C, Schmader K (1998) The association of weight change in Alzheimer's disease with severity of disease and mortality: A longitudinal analysis. *J Am Geriatr Soc* 46, 1223–1227. [PubMed: 9777903]
- [26]. Albanese E, Taylor C, Siervo M, Stewart R, Prince MJ, Acosta D (2013) Dementia severity and weight loss: A comparison across eight cohorts. The 10/66 study. *Alzheimers Dement* 9, 649–656. [PubMed: 23474042]
- [27]. Burns JM, Johnson DK, Watts A, Swerdlow RH, Brooks WM (2010) Reduced lean mass in early Alzheimer disease and its association with brain atrophy. *Arch Neurol* 67, 428–343. [PubMed: 20385908]
- [28]. White H, Pieper C, Schmader K, Fillenbaum G (1996) Weight change in Alzheimer's disease. *J Am Geriatr Soc* 44, 265–72. [PubMed: 8600194]
- [29]. Johnson DK, Wilkins CH, Morris JC (2006) Accelerated weight loss may precede diagnosis in Alzheimer disease. *Arch Neurol* 63, 1312–7. [PubMed: 16966511]
- [30]. Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, Jr CRJ (2007) 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. *Brain* 130, 1777–1786. [PubMed: 17533169]
- [31]. Barrett-Connor E, Edelman SL, Corey-Bloom J, Wiederholt WC (1996) Weight loss precedes dementia in community-dwelling older adults. *J Am Geriatr Soc* 44, 1147–1152. [PubMed: 8855991]
- [32]. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA (2005) Change in body mass index and risk of incident Alzheimer disease. *Neurology* 65, 892–897. [PubMed: 16186530]
- [33]. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: Implications for Alzheimer's disease intervention. *J Neurosci* 24, 11120–11126. [PubMed: 15590928]
- [34]. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs C V, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. *FASEB J* 18, 902–904. [PubMed: 15033922]
- [35]. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman E a, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain *in vivo*. *Proc Natl Acad Sci U S A* 100, 4162–4167. [PubMed: 12634421]

- [36]. McClean PL, Parthasarathy V, Faivre E, Hölscher C (2011) The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. *J Neurosci* 31, 6587–6594. [PubMed: 21525299]
- [37]. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. *Neuron* 40, 1087–1093. [PubMed: 14687544]
- [38]. Jolivald CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E (2010) Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. *Exp Neurol* 223, 422–431. [PubMed: 19931251]
- [39]. Hsu DC, Mormino EC, Schultz AP, Amariglio RE, Donovan NJ, Rentz DM, Johnson KA, Sperling RA, Marshall GA (2016) Lower late-life body-mass index is associated with higher cortical amyloid burden in clinically normal elderly. *J Alzheimers Dis* 53, 1097–1105. [PubMed: 27340843]
- [40]. Vidoni ED, Townley RA, Honea RA, Burns JM, Alzheimer's Disease Neuroimaging Initiative (2011) Alzheimer disease biomarkers are associated with body mass index. *Neurology* 77, 1913–1920. [PubMed: 22105948]
- [41]. Buchman AS, Schneider JA, Wilson RS, Bienias JL, Bennett DA (2006) Body mass index in older persons is associated with Alzheimer disease pathology. *Neurology* 67, 1949–1954. [PubMed: 17159099]
- [42]. Grundman M, Corey-Bloom J, Jernigan T, Archibald S, Thal LJ (1996) Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy. *Neurology* 46, 1585–1591. [PubMed: 8649553]
- [43]. Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, Minthon L, Trojanowski JQ, Shaw LM, Faluyi YO, Vellas B, Dubois B, Blennow K, Buerger K, Teipel SJ, Weiner M, Hampel H, Alzheimer's Disease Neuroimaging Initiative (2012) Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. *Neurobiol Aging* 33, 1599–1608. [PubMed: 21684041]
- [44]. Toledo JB, Toledo E, Weiner MW, Jack CR, Jagust W, Lee VMY, Shaw LM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2012) Cardiovascular risk factors, cortisol, and amyloid- β deposition in Alzheimer's Disease Neuroimaging Initiative. *Alzheimers Dement* 8, 483–489. [PubMed: 23102118]
- [45]. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. *Neurology* 43, 2412–2414.
- [46]. Fischl B (2012) FreeSurfer. *Neuroimage* 62, 774–781. [PubMed: 22248573]
- [47]. Su Y, D'Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, Blazey TM, Christensen JJ, Vora S, Morris JC, Mintun MA, Benzinger TLS (2013) Quantitative analysis of PiB-PET with FreeSurfer ROIs. *PLoS One* 8, e73377. [PubMed: 24223109]
- [48]. Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, Bateman RJ, Cairns NJ, Aldea P, Cash L, Christensen JJ, Friedrichsen K, Hornbeck RC, Farrar AM, Owen CJ, Mayeux R, Brickman AM, Klunk W, Price JC, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Schofield PR, Buckles V, Morris JC, Benzinger TLS (2015) Partial volume correction in quantitative amyloid imaging. *Neuroimage* 107, 55–64. [PubMed: 25485714]
- [49]. Rousset OG, Ma Y, Evans AC (1998) Correction for partial volume effects in PET: Principle and validation. *J Nucl Med* 39, 904–911. [PubMed: 9591599]
- [50]. Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Xiong C, Morris JC, Benzinger TLS (2018) Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. *Neuroimage Clin* 19, 406–416. [PubMed: 30035025]
- [51]. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA (2015) The Centiloid project: Standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement* 11, 1–15.e4. [PubMed: 25443857]
- [52]. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ, American College of Cardiology/American Heart

- Association Task Force on Practice Guidelines, Obesity Society (2014) 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. *J Am Coll Cardiol* 63, 2985–3023. [PubMed: 24239920]
- [53]. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann Neurol* 67, 122–131. [PubMed: 20186853]
- [54]. World Health Organization. Global Database on Body Mass Index.
- [55]. Liu C- C, Zhao N, Fu Y, Wang N, Linares C, Tsai C- W, Bu G (2017) ApoE4 accelerates early seeding of amyloid pathology. *Neuron* 96, 1024–1032.e3. [PubMed: 29216449]
- [56]. Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, Benzinger TLS, Gordon BA (2018) Longitudinal brain imaging in preclinical Alzheimer disease: Impact of APOE ϵ 4 genotype. *Brain* 141, 1828–1839. [PubMed: 29672664]
- [57]. Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, Rentz DM, Johnson KA, Sperling RA, Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study (2014) Amyloid and APOE ϵ 4 interact to influence short-term decline in preclinical Alzheimer disease. *Neurology* 82, 1760–1767. [PubMed: 24748674]
- [58]. Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, Johnson KA, Sperling RA (2014) Synergistic effect of β -amyloid and neurodegeneration on cognitive decline in clinically normal individuals. *JAMA Neurol* 71, 1379. [PubMed: 25222039]
- [59]. Vos SJB, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM (2013) Preclinical Alzheimer's disease and its outcome: A longitudinal cohort study. *Lancet Neurol* 12, 957–965. [PubMed: 24012374]
- [60]. Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, Lowe VJ, Knopman DS, Pankratz VS, Machulda MM, Geda YE, Jack CR (2016) Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. *JAMA Neurol* 73, 85–92. [PubMed: 26595683]
- [61]. Blautzik J, Kotz S, Brendel M, Sauerbeck J, Vettermann F, Winter Y, Bartenstein P, Ishii K, Rominger A (2018) Relationship between body mass index, ApoE4 status, and PET-based amyloid and neurodegeneration markers in amyloid-positive subjects with normal cognition or mild cognitive impairment. *J Alzheimers Dis* 65, 781–791. [PubMed: 28697560]
- [62]. Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A, Santucci Chadha A, Baracchi F, Girouard H, Misoch S, Giacobini E, Depypere H, Hampel H, Women's Brain Project and the Alzheimer Precision Medicine Initiative (2018) Sex differences in Alzheimer disease - the gateway to precision medicine. *Nat Rev Neurol* 14, 457–469. [PubMed: 29985474]
- [63]. Laws KR, Irvine K, Gale TM (2018) Sex differences in Alzheimer's disease. *Curr Opin Psychiatry* 31, 133–139. [PubMed: 29324460]
- [64]. Koran MEI, Wagener M, Hohman TJ, Alzheimer's Neuroimaging Initiative (2017) Sex differences in the association between AD biomarkers and cognitive decline. *Brain Imaging Behav* 11, 205–213. [PubMed: 26843008]
- [65]. Schmidt R, Kienbacher E, Benke T, Dal-Bianco P, Delazer M, Ladurner G, Jellinger K, Marksteiner J, Ransmayr G, Schmidt H, Stögmann E, Friedrich J, Wehringer C (2008) [Sex differences in Alzheimer's disease]. *Neuropsychiatr* 22, 1–15. [PubMed: 18381051]
- [66]. Mazure CM, Swendsen J (2016) Sex differences in Alzheimer's disease and other dementias. *Lancet Neurol* 15, 451–452. [PubMed: 26987699]
- [67]. Albanese E, Launer LJ, Egger M, Prince MJ, Giannakopoulos P, Wolters FJ, Egan K (2017) Body mass index in midlife and dementia: Systematic review and meta-regression analysis of 589,649 men and women followed in longitudinal studies. *Alzheimers Dement (Amst)* 8, 165–178. [PubMed: 28761927]
- [68]. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, Winblad B, Helkala E- L, Tuomilehto J, Soininen H, Nissinen A (2005) Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. *Arch Neurol* 62, 1556–1560. [PubMed: 16216938]
- [69]. Gustafson D (2006) Adiposity indices and dementia. *Lancet Neurol* 5, 713–720. [PubMed: 16857578]

- [70]. Kerwin DR, Gaussoin SA, Chlebowski RT, Kuller LH, Vitolins M, Coker LH, Kotchen JM, Nicklas BJ, Wassertheil-Smoller S, Hoffmann RG, Espeland MA (2011) Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: Results from the Women's Health Initiative Memory Study. *J Am Geriatr Soc* 59, 107–112. [PubMed: 21226681]
- [71]. Scarmeas N, Luchsinger JA, Brickman AM, Cosentino S, Schupf N, Xin-Tang M, Gu Y, Stern Y (2011) Physical activity and Alzheimer disease course. *Am J Geriatr Psychiatry* 19, 471–481. [PubMed: 20808142]




Fig. 1. Scatter plot of BMI and cortical A β burden by age group. The scatter plot reflects raw values for ease of interpretation. Late-life participants are dark circles, and mid-life participants are grey triangles. Lines of best fit are also shown.




Fig. 2.

Partial regression plot from primary analysis of BMI and cortical A β burden (as measured in Centiloid units) in mid- and late-life individuals. The model was adjusted for age, sex, years of education, and APOE4 carrier status. Standardized residuals for Centiloid units were calculated after regressing cortical A β burden against all the independent variables except BMI while standardized residuals for BMI were calculated after regressing BMI against the remaining independent variables. BMI was significant in the late-life model but not the mid-life model. These results remained the same even after exclusion of the four individuals with highest BMI.




Fig. 3.

Boxplots of the distributions of cortical A β burden in each of the three BMI groups in late-life (A) and mid-life (B) individuals. Pairwise comparisons are denoted as N.S. $p > 0.05$ and *** $p < 0.001$.




Fig. 4. Scatterplot of BMI and cortical A β burden within APOE4 subdivisions in mid-life (A) and late-life (B). The scatter plots reflect raw values for ease of interpretation. E4 non-carriers are black circles, and E4 carriers are grey triangles. Lines of best fit are also shown. The BMI \times APOE4 interaction term was not significant in the mid-life ($\beta = 0.33$, $p = 0.296$) or the late-life ($\beta = 0.29$, $p > 0.5$) groups.

Table 1Demographics of Mid-Life and Late-life Knight ADRC cohorts with A β PET

Characteristic	Mid-Life	Late-life
N	96	277
Age: mean (range)	53.5 (45–60)	71.4 (61–100)
Sex (% female)	72.9%	59.9%
Years of Education: mean (range)	16.3 (6–24)	15.8 (8–24)
APOE4 Status (% carriers)	35.4%	28.5%
Body Mass Index	27.7 (18.6–44.3)	27.5 (14.1–58.7)
Underweight (BMI <18.5)	0.0% (<i>n</i> = 0)	1.8% (<i>n</i> = 5)
Normal (BMI 18.5 – 24.9)	35.5% (<i>n</i> = 34)	38.6% (<i>n</i> = 107)
Overweight (BMI 25 – 29.9)	40.6% (<i>n</i> = 39)	33.6% (<i>n</i> = 93)
Obese (BMI >30)	24.0% (<i>n</i> = 23)	26.0% (<i>n</i> = 72)
Centiloid value: mean(range)	–0.96 (–8.5 – 47.1)	13.5 (–16.6 – 131.05)
MMSE score: mean (standard deviation)	28.9 (4.3)	28 (2.2)
CDR-SOB: mean (standard deviation)	0.0053 (0.052)	0.033 (0.15)

MMSE, Mini-Mental State Examination; CDR-SOB, Clinical Dementia Rating Sum of Boxes.

Table 2

Summary of additional analyses. All models adjusted for age (or age-group), sex, years of education, and APOE4 status

Model	Term	β	<i>p</i>
BMI \times Age-Group Model	BMI \times Age-Group	-	0.0309
	Normal BMI	-	-
BMI Subdivision Model (Late-life)	Overweight BMI	-7.7	0.0499
	Obese BMI	-12.4	0.0033
BMI \times APOE4 Models	BMI \times APOE4+ (late-life)	0.29	>0.5
	BMI \times APOE4+ (mid-life)	0.33	0.296
BMI \times Sex Models	BMI \times male (late-life)	0.50	0.43
	BMI \times male (mid-life)	0.64	0.13